Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Press Releases

Date Title and Summary
Toggle Summary Rexahn Announces License Agreement with Rexgene
Rockville, MD, March 18, 2003 – Rexahn Corp. announced today that it has signed a Research Collaboration Agreement with Rexgene Biotech Co. Ltd, a Korean biotech company headquartered in Seoul, Korea. The agreement provides for the companies to develop a research and development plan for the
Toggle Summary Rexahn Announces Filing of a Patent Application for a Novel Anti-Cancer
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has submitted a patent application for its recently discovered anti-cancer drug, RX-0047. The new drug candidate inhibits expression of HIF-1, a human protein that leads to rapid cancer growth.
Toggle Summary Rexahn Announces Joint Research Agreement with The KRICT
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has entered into a joint research agreement with the Korea Research Institute of Chemical Technology (KRICT), a quasi-government research institute in Korea. The purpose of this collaboration is to accelerate the discovery of

Events & Presentations

Date Event Details
Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]

Summary Toggle Apr 14-18, 2018 Apr 14, 2018 04/14/18

Title: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 [View Poster]


Chicago, Illinois
Summary Toggle Jan 9, 2018
12:00 AM PST
Jan 9, 2018 12:00 AM PST 01/09/18

©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy